For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome.
Custom Services utilizes RabMAb technology, Abcam’s patented antibody technology, for the development of high quality rabbit monoclonals.
Our team has a demonstrated record of success developing rabbit monoclonal antibodies (links to “monoclonal” antibody generation process) against challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds. More than 550 institutions and 150 pharma and biotech companies have benefited from our custom services.
Submit immunogens as recombinant proteins, synthetic peptides, small molecules, cDNA expression vectors, cells or even pathological tissue samples. Alternatively, you can provide the spleen of an immunized rabbit to initiate the monoclonal phase of antibody development. Or better yet, you can simply provide the target information and we will produce the immunogens.
View antibody generation timeline --> links to antibody generation timeline
We also provide comprehensive services for antibody cloning, engineering, expression, and purification in addition to generating custom rabbit monoclonal antibodies.
View custom service offerings --> links to custom service offerings table
The rabbit immune system generates antibody diversity and optimizes affinity by mechanisms different from those of mice and other rodents. RabMAb technology produces reagents that combine the superior antigen recognition of a rabbit antibody with the specificity and consistency of a monoclonal. Two major advantages that set these apart from traditional mouse and rabbit antibodies are:
High Specificity: Immunization of rabbits results in a highly diverse suite of B-lymphocytes and an abundance of splenocytes. The breadth of available cells means a greater chance of finding antibodies that distinguish between similar molecules and therefore improved specificity.
Harness the RabMAb advantages to make antibodies that are:
RabMAb technology is the only available hybridoma-based technology for making rabbit monoclonals. We have developed a unique and proprietary method for making monoclonal antibodies from rabbits that is distinct from the conventional method of starting with mice.